SteadyMed (NSDQ:STDY) said yesterday that it finished a clinical study for its lead drug candidate, Trevyent. The pulmonary arterial hypertension treatment is a combination of treprostinil and the PatchPump prefilled, disposable infusion system.
The San Ramon, Calif.-based company said it is on track to submit a New Drug Application for Trevyent in the 2nd quarter of 2017.
Get the full story at our sister site, Drug Delivery Business News.
The post SteadyMed studies accuracy and precision of PatchPump infusion system for Trevyent appeared first on MassDevice.